Survivin

Licensing deal with Dx&Vx for OVM-200 in South Korea and China

Ongoing discussions at an advanced stage with leading shareholder DxVx, to license OVM-200 for South Korea and for China. Oxford, UK – 28th November 2023 Press Release – Licensing deal with Dx&Vx for OVM-200 in South Korea and China Oxford Vacmedix (OVM), the UK-based biopharma company developing vaccines to treat cancer announced today ongoing licensing discussions with its largest shareholder DxVx for lead cancer vaccine OVM-200. If concluded the licensing deal will grant DxVx...
Read More

New publication highlights importance of survivin as target and potential for combination use to treat cancer

A new publication in Advanced Therapeutics comprehensively reviews the rationale and preclinical results for OVM-200 both alone and in combination. Oxford, UK – 10th October 2023 Press Release – Importance of Survivin as a target and potential for combination use to treat cancer Oxford Vacmedix (OVM), the UK-based biopharma company focused on the development of vaccines to treat cancer announced today the publication of a key research paper on its lead cancer vaccine,  OVM-200. The...
Read More

Survivin as a biological biomarker for diagnosis and therapy

Survivin (SVN) is a member of the inhibitor of apoptosis (IAP) protein family that promotes cellular proliferation and inhibits apoptosis. Overexpression of SVN is associated with autoimmune disease, hyperplasia, and tumors and can be used as a biomarker in these diseases. SVN is widely recognized as a tumor-associated antigen (TAA) and has become an important target for cancer diagnosis and treatment. Read the full article: Survivn as a biological biomarker for diagnosis and therapy By: Yuming...
Read More
en_GBEnglish